Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of “Moderate Buy” by Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-eight analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-three have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $477.4420.

ALNY has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. The Goldman Sachs Group upped their price target on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a report on Tuesday, September 16th. BMO Capital Markets raised their price objective on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 10th. Finally, Barclays raised their price target on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an “overweight” rating in a research report on Friday, October 31st.

Alnylam Pharmaceuticals Trading Up 2.8%

NASDAQ:ALNY opened at $410.00 on Friday. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $495.55. The company has a market cap of $54.17 billion, a PE ratio of 1,708.33 and a beta of 0.30. The firm has a 50-day moving average of $441.01 and a 200-day moving average of $412.70.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,650 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total value of $7,100,248.50. Following the completion of the transaction, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at $29,675,409.21. This represents a 19.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the sale, the executive vice president directly owned 54,052 shares of the company’s stock, valued at $24,434,206.60. The trade was a 6.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 60,328 shares of company stock worth $27,288,993. 1.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Groupama Asset Managment raised its holdings in shares of Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after purchasing an additional 2,483,697 shares during the period. Norges Bank purchased a new stake in Alnylam Pharmaceuticals in the second quarter worth $662,837,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Alnylam Pharmaceuticals by 698.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after buying an additional 1,185,909 shares during the period. Qube Research & Technologies Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $369,943,000. Finally, Holocene Advisors LP bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $194,616,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.